EL CAJON, Calif. - PURE Bioscience, Inc. (OTCQB: PURE), known for its patented silver dihydrogen citrate (SDC) antimicrobial technology, announced the appointment of Darin Zehr to its Board of Directors. Mr. Zehr, who began his tenure on May 1, 2024, is joining as an independent director and will also serve on the company's Audit Committee and Compensation Committee.
Bringing over three decades of experience in the food industry, Zehr's expertise spans food quality and safety, sanitation, and operations management. He currently holds the position of General Manager at Commercial Food Sanitation LLC (CFS), a global food safety consulting and training organization. His previous experience includes a 22-year tenure at Kraft Foods (NASDAQ:KHC) in various operational roles, including Area Sanitation Manager and Plant Manager.
Zehr, who also contributes to non-profit and healthcare boards, expressed his enthusiasm about joining PURE Bioscience, highlighting the value of the company's product line. CEO Robert Bartlett welcomed Zehr's appointment, citing the value of his extensive food industry experience and insights for the board.
PURE Bioscience focuses on developing antimicrobial products for the food safety sector, aiming to address health and environmental challenges associated with pathogen and hygiene control. The company's SDC technology is promoted as a non-toxic, broad-spectrum antimicrobial agent that can be combined with other compounds and offers advantages over existing market products in terms of efficacy, reduced toxicity, and mitigation of bacterial resistance.
The information provided is based on a press release statement from PURE Bioscience. The company's forward-looking statements indicate plans for continued product development and market expansion, subject to regulatory approvals and market acceptance. These statements are inherently subject to risks and uncertainties that could affect the company's actual results.
InvestingPro Insights
In light of the recent appointment of Darin Zehr to PURE Bioscience's Board of Directors, investors may find the latest metrics from InvestingPro particularly relevant. As of the second quarter of 2024, PURE Bioscience has a market capitalization of $7.83 million, reflecting the market's current valuation of the company. Despite the company's focus on innovative antimicrobial technology for the food safety sector, PURE Bioscience's P/E ratio stands at -2.32, suggesting that the company is currently not profitable.
The company's revenue growth in the last twelve months as of Q2 2024 has been positive at 14.02%, indicating an upward trend in sales. However, this is contrasted by a quarterly revenue decline of -17.88% in Q2 2024, which may be a point of concern for investors. Additionally, the gross profit margin for the same period is substantial at 55.23%, showcasing the company's ability to retain a significant portion of its sales as gross profit.
For investors seeking deeper insights and more comprehensive analysis, InvestingPro offers additional tips on evaluating companies like PURE Bioscience. With a current total of 7 additional InvestingPro Tips available, subscribers can gain a richer understanding of the company's financial health and future prospects. Those interested in accessing these tips can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking valuable information for making informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.